Show simple item record

dc.contributor.authorEdinoff, A.N.
dc.contributor.authorSwinford, C.R.
dc.contributor.authorOdisho, A.S.
dc.contributor.authorBurroughs, C.R.
dc.contributor.authorStark, C.W.
dc.contributor.authorRaslan, W.A.
dc.contributor.authorCornett, E.M.
dc.contributor.authorKaye, A.M.
dc.contributor.authorKaye, A.D.
dc.date.accessioned2023-01-31T18:18:49Z
dc.date.available2023-01-31T18:18:49Z
dc.date.issued2022
dc.identifier.citationEdinoff, A. N., Swinford, C. R., Odisho, A. S., Burroughs, C. R., Stark, C. W., Raslan, W. A., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychology Research, 10(4).
dc.identifier.issn2420-8124
dc.identifier.doi10.52965/001c.39576
dc.identifier.urihttp://hdl.handle.net/10150/667894
dc.description.abstractMonoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible to reversible and selective to non-selective, these drugs target the monoamine oxidase (MAO) enzyme and prevent the oxidative deamination of various monoamines and catecholamines such as serotonin and dopamine, respectively. Tyramine is a potent releaser of norepinephrine (NE) and is found in high concentrations in foods such as aged cheeses and meats. Under normal conditions, NE is unable to accumulate to toxic levels due to the presence of MAO-A, an enzyme that degrades neurotransmitters, including NE. When MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8-10 mg of tyramine ingested and can result in life-threatening blood pressure elevations. In addition to adverse reactions with certain foods, both older and newer MAOIs can negatively interact with both sympathomimetic and serotonergic drugs. In general, patients on a MAOI want to avoid two types of medications: those that can elevate blood pressure via sympathomimetic actions (e.g., phenylephrine and oxymetazoline) and those that can increase serotonin levels via 5-HT reuptake inhibition (e.g., dextromethorphan, chlorpheniramine, and brompheniramine). Illicit drugs that stimulate the central nervous system such as ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act as serotonin releasers. Patient involvement is also crucial to ensure any interaction within the healthcare setting includes making other providers aware of a MAOI prescription as well as avoiding certain OTC medications that can interact adversely with MAOIs. © 2022, Open Medical Publishing. All rights reserved.
dc.language.isoen
dc.publisherOpen Medical Publishing
dc.rightsCopyright © 2022 The Author(s). Open Medical Publishing has chosen to apply the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published under its name.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectbleeding
dc.subjectdrug interactions
dc.subjectecstasy
dc.subjectheadache
dc.subjecthypertensive crisis
dc.subjectinsomnia
dc.subjectMonoamine oxidase inhibitors
dc.subjectsexual dysfunction
dc.subjectweight gain
dc.titleClinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
dc.typeArticle
dc.typetext
dc.contributor.departmentCollege of Medicine-Tucson, University of Arizona
dc.identifier.journalHealth Psychology Research
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleHealth Psychology Research
refterms.dateFOA2023-01-31T18:18:51Z


Files in this item

Thumbnail
Name:
39576-clinically-relevant-drug ...
Size:
392.2Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © 2022 The Author(s). Open Medical Publishing has chosen to apply the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published under its name.
Except where otherwise noted, this item's license is described as Copyright © 2022 The Author(s). Open Medical Publishing has chosen to apply the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published under its name.